Get to know our clinical trials
Trial of TEV-56286 for the treatment of patients with multiple system atrophy
THE PURPOSE OF THIS CLINICAL TRIAL IS TO DETERMINE WHETHER AN INVESTIGATIONAL DRUG CALLED TEV-56286 (ALSO KNOWN AS ANLE138B) CAN STABILIZE, LIMIT OR SLOW THE WORSENING OF MSA SYMPTOMS, AND TO DETERMINE THE SAFETY AND TOLERABILITY OF THIS DRUG IN ADULTS WITH MSA COMPARED TO PLACEBO.
Technical Summary
- PHASE II, MULTICENTER, DOUBLE-MASKED, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF TEV-56286 FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY
- Code EudraCT: 2023-505320-54-00
- Protocol number: TV56286-NDG-20039
- Promoter: Teva Pharmaceutical Industries, Ltd
- Molecule/Drug: TEV-56286
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.